ImmuRAIT-CEA-rhenium-188 (Immunomedics)

N/A

Report date: 2025/11/24 11:49:04

Base Information

Drug NameImmuRAIT-CEA-rhenium-188 (Immunomedics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Rhenium > 188Re +[4]

Mechanisms of ActionCarcinoembryonic antigen modulators

TargetsCarcinoembryonic antigen

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A